Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial
Roseanne D Dobkin, Sarah L Mann, Michael A Gara, Alejandro Interian, Kailyn M Rodriguez, Matthew Menza, Roseanne D Dobkin, Sarah L Mann, Michael A Gara, Alejandro Interian, Kailyn M Rodriguez, Matthew Menza
Abstract
Objective: To determine whether, for patients with depression and Parkinson disease (PD), telephone-based cognitive-behavioral treatment (T-CBT) alleviates depressive symptoms significantly more than treatment as usual (TAU), we conducted a randomized controlled trial to evaluate the efficacy of a 10-session T-CBT intervention for depression in PD, compared to TAU.
Methods: Seventy-two people with PD (PWP) were randomized to T-CBT + TAU or TAU only. T-CBT tailored to PWPs' unique needs was provided weekly for 3 months, then monthly during 6-month follow-up. CBT targeted negative thoughts (e.g., "I have no control"; "I am helpless") and behaviors (e.g., social withdrawal, excessive worry). It also trained care partners to help PWP practice healthy habits. Blind raters assessed outcomes at baseline, midtreatment, treatment end, and 1 and 6 months post-treatment. Analyses were intent to treat.
Results: T-CBT outperformed TAU on all depression, anxiety, and quality of life measures. The primary outcome (Hamilton Depression Rating Scale score) improved significantly in T-CBT compared to TAU by treatment end. Mean improvement from baseline was 6.53 points for T-CBT and -0.27 points for TAU (p < 0.0001); gains persisted over 6-month follow-up (p < 0.0001). Improvements were moderated by a reduction in negative thoughts in the T-CBT group only, reflecting treatment target engagement.
Conclusions: T-CBT may be an effective depression intervention that addresses a significant unmet PD treatment need and bypasses access barriers to multidisciplinary, evidence-based care.
Clinicaltrialsgov identifier: NCT02505737.
Classification of evidence: This study provides Class I evidence that for patients with depression and PD, T-CBT significantly alleviated depressive symptoms compared to usual care.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
References
- Weintraub D, Mamikonyan E. The neuropsychiatry of Parkinson disease: a perfect storm. Am J Geriatr Psychiatry 2019;27:998–1018.
- Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:377–382.
- Ravina B, Camicioli R, Como PG, et al. . The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69:342–347.
- Straka I, Minár M, Gažová A, Valkovič P, Kyselovič J. Clinical aspects of adherence to pharmacotherapy in Parkinson disease: a PRISMA-compliant systematic review. Medicine 2018;97:e10962.
- Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff J, Giladi N. Falls in outpatients with Parkinson's disease. J Neurol 2005;252:1310–1315.
- Qureshi SU, Amspoker AB, Calleo JS, Kunik ME, Marsh L. Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression. J Geriatr Psychiatry Neurol 2012;25:233–239.
- McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson's disease. Mov Disord 2007;22:804–812.
- Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G. Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord 2008;23:1420–1427.
- Balestrino R, Martinez-Martin P. Reprint of “Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease.” J Neurol Sci 2017;374:3–8.
- Pontone GM, Bakker CC, Chen S, et al. . The longitudinal impact of depression on disability in Parkinson disease. Int J Geriatr Psychiatry 2016;31:458–465.
- Landau S, Harris V, Burn D, et al. . Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis. Psychol Med 2016;46:657–667.
- Lachner C, Armstrong MJ, Gruber-Baldini AL, et al. . Discordance between physician assessment and patient-reported depressive symptoms in Parkinson disease. J Geriatr Psychiatry Neurol 2017;30:191–195.
- Seppi K, Ray Chaudhuri K, Coelho M, et al. . Update on treatments for nonmotor symptoms of Parkinson's disease: an evidence‐based medicine review. Mov Disord 2019;34:180–198.
- Hinnell C, Hurt CS, Landau S, Brown RG, Samuel M, Group PPS. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson's disease? Mov Disord 2012;27:236–241.
- Beck AT. Cognitive Therapy of Depression. New York: Guilford Press; 1979.
- Swalwell C, Pachana NA, Dissanayaka NN. Remote delivery of psychological interventions for Parkinson's disease. Int psychogeriatrics 2018;30:1783–1795.
- Koychev I, Okai D. Cognitive–behavioural therapy for non-motor symptoms of Parkinson's disease: a clinical review. Evidence-Based Ment Health 2017;20:15–20.
- Dobkin RD, Menza M, Allen LA, et al. . Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066–1074.
- Oehlberg K, Barg FK, Brown GK, Taraborelli D, Stern MB, Weintraub D. Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study. J Geriatr Psychiatry Neurol 2008;21:123–132.
- Dobkin RD, Rubino JT, Friedman J, Allen LA, Gara MA, Menza M. Barriers to mental health care utilization in Parkinson's disease. J Geriatr Psychiatry Neurol 2013;26:105–116.
- Dorsey ER, Glidden AM, Holloway MR, Birbeck GL, Schwamm LH. Teleneurology and mobile technologies: the future of neurological care. Nat Rev Neurol 2018;14:285.
- Titova N, Chaudhuri KR. Personalized medicine in Parkinson's disease: time to be precise. Mov Disord 2017;32:1147.
- Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–39.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington: American Psychiatric Press; 2013.
- First MB, Spitzer RL, Gibbon M, Williams JB. User's Guide for the Structured Clinical Interview for DSM-IV axis I Disorders SCID-I: Clinician Version. Washington: American Psychiatric Press; 1997.
- Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006;21:148–158.
- Dalrymple-Alford J, MacAskill M, Nakas C, et al. . The MoCA well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717–1725.
- Hamilton M. Hamilton Depression Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised Edition. Rockville: National Institute of Mental Health; 1976: 179–192.
- Frank E, Prien RF, Jarrett RB, et al. . Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851–855.
- Hamilton M. The assessment of anxiety status by rating. Br J Med Psychol 1959;32:50–55.
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I: conceptual framework and item selection. Med Care 1992;30:473–483.
- Fereshtehnejad S-M. Strategies to maintain quality of life among people with Parkinson's disease: what works? Neurodegenerative Dis Manag 2016;6:399–415.
- Alloy LB, Abramson LY, Hogan ME, et al. . The Temple-Wisconsin Cognitive Vulnerability to Depression Project: lifetime history of axis I psychopathology in individuals at high and low cognitive risk for depression. J Abnorm Psychol 2000;109:403.
- Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. JAMA 2002;288:2469–2475.
- Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach. New York: Guilford Publications; 2017.
- Freedland KE, Mohr DC, Davidson KW, Schwartz JE. Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosomatic Med 2011;73:323–335.
- Fernie BA, Kollmann J, Brown RG. Cognitive behavioural interventions for depression in chronic neurological conditions: a systematic review. J Psychosomatic Res 2015;78:411–419.
- Gould RL, Coulson MC, Howard RJ. Cognitive behavioral therapy for depression in older people: a meta‐analysis and meta‐regression of randomized controlled trials. J Am Geriatr Soc 2012;60:1817–1830.
- Wiles N, Thomas L, Abel A, et al. . Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013;381:375–384.
- Kornstein SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry 2001;62:18–25.
- Schulman‐Green D, Jaser SS, Park C, Whittemore R. A metasynthesis of factors affecting self‐management of chronic illness. J Adv Nurs 2016;72:1469–1489.
- Julien CL, Rimes KA, Brown RG. Rumination and behavioural factors in Parkinson's disease depression. J Psychosom Res 2016;82:48–53.
- Dimidjian S, Barrera M Jr, Martell C, Munoz RF, Lewinsohn PM. The origins and current status of behavioral activation treatments for depression. Annu Rev Clin Psychol 2011;7:1–38.
- Bucks R, Cruise K, Skinner T, Loftus A, Barker R, Thomas M. Coping processes and health‐related quality of life in Parkinson's disease. Int J Geriatr Psychiatry 2011;26:247–255.
- Cuijpers P, Reijnders M, Huibers MJ. The role of common factors in psychotherapy outcomes. Annu Rev Clin Psychol 2018;15:207–231.
- Moore KA, Seeney F. Biopsychosocial predictors of depressive mood in people with Parkinson's disease. Behav Med 2007;33:29–38.
- Dobkin RD, Mann SL, Interian A, Gara MA, Menza M. Cognitive behavioral therapy improves diverse profiles of depressive symptoms in Parkinson's disease. Int J Geriatr Psychiatry 2019;34:722–729.
- Dobkin RD, Rubino JT, Allen LA, et al. . Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson's disease. J Consult Clin Psychol 2012;80:694.
- American Telemedicine Association. 2019 State of the States: Coverage and Reimbursement. Washington: American Telemedicine Association; 2019.
- The Michael J. Fox Foundation for Parkinson’s Research. Our Public Policy Priorities. New York: The Michael J. Fox Foundation for Parkinson’s Research. Accessed August 1, 2019.
Source: PubMed